Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBIT (2020 - 2025)

Apellis Pharmaceuticals has reported EBIT over the past 6 years, most recently at -$51.1 million for Q4 2025.

  • Quarterly results put EBIT at -$51.1 million for Q4 2025, down 152.45% from a year ago — trailing twelve months through Dec 2025 was $55.4 million (up 234.18% YoY), and the annual figure for FY2025 was $55.4 million, up 234.17%.
  • EBIT for Q4 2025 was -$51.1 million at Apellis Pharmaceuticals, down from $223.2 million in the prior quarter.
  • Over the last five years, EBIT for APLS hit a ceiling of $322.0 million in Q4 2023 and a floor of -$194.3 million in Q2 2021.
  • Median EBIT over the past 5 years was -$101.9 million (2023), compared with a mean of -$42.4 million.
  • Biggest five-year swings in EBIT: tumbled 156.53% in 2022 and later surged 572.05% in 2025.
  • Apellis Pharmaceuticals' EBIT stood at $290.2 million in 2021, then tumbled by 156.53% to -$164.1 million in 2022, then soared by 296.3% to $322.0 million in 2023, then plummeted by 69.72% to $97.5 million in 2024, then crashed by 152.45% to -$51.1 million in 2025.
  • The last three reported values for EBIT were -$51.1 million (Q4 2025), $223.2 million (Q3 2025), and -$33.3 million (Q2 2025) per Business Quant data.